Unicycive Therapeutics posts corporate presentation on kidney disease drug pipeline, led by OLC for dialysis hyperphosphatemia
UNCY•Launch preparations and market opportunity
- Approval is targeted in the near term, with launch preparations underway across sales, marketing, reimbursement support, advocacy, and logistics.
- The company framed hyperphosphatemia as a more than $1 billion U.S. market, citing more than 550,000 U.S. dialysis patients.
- Cash runway is expected into 2027 to support potential FDA clearance and a commercial rollout.
Corporate presentation highlights OLC and NDA resubmission plans
Unicycive Therapeutics posted a corporate presentation on its kidney disease drug pipeline, led by oxylanthanum carbonate (OLC) for dialysis-related hyperphosphatemia.
- Unicycive outlined plans to resubmit its NDA for oxylanthanum carbonate, a 505(b)(2) candidate for dialysis-related hyperphosphatemia.
- FDA discussions center on a pending inspection of a third-party manufacturing vendor cited for deficiencies in a complete response letter.
